Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.

Tat SK, Pelletier JP, Vergés J, Lajeunesse D, Montell E, Fahmi H, Lavigne M, Martel-Pelletier J.

Arthritis Res Ther. 2007;9(6):R117.

3.

Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.

Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J.

Bone. 2011 Sep;49(3):559-67. doi: 10.1016/j.bone.2011.06.005.

PMID:
21700005
4.

RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.

Corrado A, Neve A, Macchiarola A, Gaudio A, Marucci A, Cantatore FP.

J Rheumatol. 2013 May;40(5):684-94. doi: 10.3899/jrheum.120845.

PMID:
23457386
5.

A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E₂ and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts.

Pecchi E, Priam S, Mladenovic Z, Gosset M, Saurel AS, Aguilar L, Berenbaum F, Jacques C.

Osteoarthritis Cartilage. 2012 Feb;20(2):127-35. doi: 10.1016/j.joca.2011.12.002.

6.

Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.

Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C.

Bone. 2009 Jun;44(6):1143-50. doi: 10.1016/j.bone.2009.02.015.

7.

Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors.

Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J.

Bone. 2008 Aug;43(2):284-91. doi: 10.1016/j.bone.2008.04.006.

8.

Local origins impart conserved bone type-related differences in human osteoblast behaviour.

Shah M, Gburcik V, Reilly P, Sankey RA, Emery RJ, Clarkin CE, Pitsillides AA.

Eur Cell Mater. 2015 Mar 4;29:155-75; discussion 175-6.

9.

Vitamins D3 and K2 may partially counterbalance the detrimental effects of pentosidine in ex vivo human osteoblasts.

Sanguineti R, Monacelli F, Parodi A, Furfaro AL, Borghi R, Pacini D, Pronzato MA, Odetti P, Molfetta L, Traverso N.

J Biol Regul Homeost Agents. 2016 Jul-Sep;30(3):713-726.

PMID:
27655488
10.

Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone.

Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, Martel-Pelletier J.

J Rheumatol. 2001 Apr;28(4):814-24.

PMID:
11327257
11.

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Enjuanes A, Ruiz-Gaspà S, Peris P, Ozalla D, Álvarez L, Combalia A, Martínez de Osaba MJ, Monegal A, Pares A, Guañabens N.

Endocrine. 2010 Feb;37(1):180-6. doi: 10.1007/s12020-009-9285-9.

PMID:
20963568
12.

Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.

Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M.

Prostate. 2007 Jun 1;67(8):840-8.

PMID:
17394194
13.

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Enjuanes A, Ruiz-Gaspà S, Peris P, Ozalla D, Alvarez L, Combalia A, Martínez de Osaba MJ, Monegal A, Pares A, Guañabens N.

Endocrine. 2010 Apr;37(2):322-8. doi: 10.1007/s12020-009-9306-8.

PMID:
20960270
14.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031.

PMID:
21925296
15.

RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis.

Giner M, Rios MA, Montoya MA, Vázquez MA, Naji L, Pérez-Cano R.

J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):46-51. doi: 10.1016/j.jsbmb.2008.11.005.

PMID:
19073256
16.

Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.

Giner M, Rios MJ, Montoya MJ, Vázquez MA, Miranda C, Pérez-Cano R.

Eur J Pharmacol. 2011 Jan 15;650(2-3):682-7. doi: 10.1016/j.ejphar.2010.10.058.

PMID:
21050847
17.

Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.

Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC.

J Bone Miner Res. 2005 Nov;20(11):2036-43.

18.

Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation.

Igarashi M, Sakamoto K, Nagaoka I.

Int J Mol Med. 2011 Sep;28(3):373-9. doi: 10.3892/ijmm.2011.686.

PMID:
21537831
19.

Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits.

Lv Y, Xia JY, Chen JY, Zhao H, Yan HC, Yang HS, Li Q, Fan YX, Guo KJ, Chen XY.

BMC Musculoskelet Disord. 2014 Nov 6;15:370. doi: 10.1186/1471-2474-15-370.

20.

Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis.

Hilal G, Martel-Pelletier J, Pelletier JP, Ranger P, Lajeunesse D.

Arthritis Rheum. 1998 May;41(5):891-9.

PMID:
9588742
Items per page

Supplemental Content

Support Center